Pfizer Voluntarily Recalls Levoxyl - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pfizer Voluntarily Recalls Levoxyl
Company issues voluntary recall after learning of complaints of an uncharacteristic odor coming from Levoxyl bottles.


ePT--the Electronic Newsletter of Pharmaceutical Technology

King Pharmaceuticals, a wholly owned subsidiary of Pfizer, has initiated a voluntary recall of 
Levoxyl (levothyroxine sodium), which is used to treat hypothyroidism and certain types of goiter.

The company initiated the recall after learning of complaints from pharmacists and patients of an uncharacteristic odor coming from Levoxyl bottles. It was determined that the odor was caused by an oxygen-absorbing canister added to 100- and 1000-tablet pharmacy bottles to enhance the stability of the product, according to a company statement.

“Pfizer conducted a careful health assessment of the situation and concluded that this odor is not likely to cause any adverse health consequences,” said the company in its statement. “However, the company discussed this situation with the US Food and Drug Administration and decided, out of an abundance of caution, to voluntarily recall the product at the retail level.”

Levoxyl is an oral tablet used used as replacement or supplemental therapy in low thyroid function (hypothyroidism) of any cause, except transient hypothyroidism during the recovery phase of subacute thyroiditis. It is also used in the treatment or prevention of certain types of goiters and, as additional therapy, in the management of a specific thyroid cancer.

King Pharmaceuticals and Pfizer said they are working to resolve the issue as quickly as possible although it is anticipated that the company may not be able to restart production until 2014. The information was posted on FDA’s Drug Shortages website as well.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here